Cite

HARVARD Citation

    Huillard, O. et al. (n.d.). Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Expert opinion on drug safety. pp. 663-673. [Online]. 
  
Back to record